Tirzepatide injection technique: the small things that change how it feels

The clinic shows you the pen, says "press it against your stomach for ten seconds, you'll hear a click, then a second click means it's done." That's the entire technique training most people get.

This is enough to inject correctly but not enough to inject well. The difference matters more than you'd expect for how the first month feels. Here's the actual list.

Where to inject

Tirzepatide is a subcutaneous injection. Three legitimate sites:

• Abdomen (most common): two finger-widths away from the navel in any direction, anywhere on the lower belly. Avoid the dead-center umbilical area and any visible scar tissue.
• Front of thigh: the upper outer quadrant, halfway between hip and knee. Good if abdominal sites are getting tender.
• Upper outer arm: technically permitted but harder to do solo because you can't see what you're injecting; works fine if someone else is doing it.

The trial protocols all used the abdomen as the standard site. The pharmacokinetics from thigh and arm are similar; the trial data is heaviest on abdomen, so most clinicians default there.

Site rotation, what actually matters

The standard advice is "rotate sites." This is correct but vague. The useful version: don't inject in the same spot twice in a row. The same spot means the same square inch. You can stay on the same general region (lower-left abdomen, lower-right abdomen) for many weeks without harm, but pick a different square inch each week.

The reason rotation matters is lipohypertrophy, a thickening of the subcutaneous fat where chronic injections happen. Lipohypertrophy doesn't hurt but it changes drug absorption from that spot, which can produce inconsistent week-to-week effects. Rotating prevents it from forming.

A practical pattern that works: divide the lower abdomen into four quadrants. Week 1 lower-left, Week 2 lower-right, Week 3 upper-left of lower abdomen, Week 4 upper-right of lower abdomen. Then start the cycle again.

Temperature matters more than the handouts say

Inject the pen at room temperature, not straight from the fridge. The drug stings noticeably more when injected cold. Take the pen out of the fridge 30-45 minutes before injection. If you forgot, hold the pen between your hands or under your shirt for 10 minutes; that's enough.

Cold-injected tirzepatide is a recurring theme in reader email about week-one nausea or local stinging. It's not pharmacologically meaningful (the drug works the same), but the local sensation is more uncomfortable and people sometimes interpret it as "the drug isn't agreeing with me" when it's actually just temperature.

How to actually press the pen

The pen self-injects when pressed against skin and the trigger is depressed. The technique that works:

1. Pinch a small fold of skin between your thumb and forefinger, lift gently. This creates a clean target and reduces the chance of injecting into muscle below the fat. 2. Hold the pen perpendicular (90 degrees) to the skin fold, not at an angle. 3. Press until you hear or feel the first click (the spring releasing). 4. Hold for 10 full seconds. Most patient handouts say 5; the manufacturer's instructions say 10. The longer hold ensures the full dose injects, especially if the drug viscosity is on the higher end of the formulation. 5. Wait for the second click or for the dose window to fully shift (depends on pen model). This confirms full dispense. 6. Lift the pen away. Don't massage the site.

The two failure modes that produce under-dosing:

• Lifting the pen before the full hold completes. The dose continues to dispense for the full 10 seconds; pulling away early leaves drug on the skin or partially injected.
• Injecting at an angle rather than perpendicular. Side-injection can deposit some of the dose into deeper tissue or back-flush at the puncture site.

Bleeding, bruising, and what's normal

A small drop of blood at the injection site is normal. A small bruise that develops later is normal. Light pressure with a clean tissue for 30 seconds typically resolves both.

What's not normal:

• Significant bleeding that requires more than light pressure
• A large or expanding bruise
• A red, warm, painful area that develops over the following 24-48 hours (this is a possible infection and worth a call to the clinic)
• A persistent firm lump at the injection site that doesn't soften within 48 hours

These are uncommon. Most people inject tirzepatide weekly for years without any of these issues.

The injection site rash question

A small minority of patients develop a mild local rash or itchy spot at injection sites. It usually resolves within 24-48 hours. If it persists or worsens, the cause is sometimes the injection itself, sometimes the alcohol swab, sometimes the latex in some pen caps. Switching to a non-alcohol cleansing wipe and a different injection region often resolves it without changing drugs.

What the second-month version of this looks like

By month two, most people have stopped thinking about technique. The pen becomes routine. This is fine; the things that matter most are temperature (room temp, not cold) and rotation (different square inch each week). Everything else is minor optimization.

One note for month-two-and-beyond: if your injection site sensation has changed (more painful, less reliable absorption, suddenly burning), the most likely cause is lipohypertrophy starting to form in your favored region. Switch to a different region for 6-8 weeks and the tissue normalizes.